AnemiaQFSNCT03853304
Quadruple Fortified Salt Trial in India
A study testing + Folic acid, + Vitamin B12 and DFS in people with Anemia and Folate Deficiency, run by Cornell University at 1 site in India.
Trial summary
Women of reproductive age are at an increased risk of anemia and micronutrient deficiencies. Evidence supports the role of periconceptional nutrition in the development of neural tube defects and other pregnancy complications. Read more about this study
- Who is it for?
- Ages 18 to 49 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Anemia, Folate Deficiency, Vitamin B 12 Deficiency
- What is being tested?
- + Folic acid, + Vitamin B12 and DFS
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 1 siteIndia
- Study dates
- 1 Oct 2023to Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 49 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Women between 18 and 49 years of age
- Healthy
- Not pregnant or lactating
- Plan to reside in the catchment area of our periconceptional surveillance program for at least two years
Who cannot join
- Severe anemia (Hemoglobin <8.0 g/dL)
- Reported diagnosis of HIV, malaria infection, or active tuberculosis disease
- Malabsorption disorders (i.e., medical conditions that may affect vitamin B12 absorption or metabolism)
- Stage 2 hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg)
- Glycated hemoglobin (HbA1c) ≥6.5%
- Other serious pre-existing medical conditions (e.g., defined as the need for regular medication use), active infections, or acute illnesses
Show all 10Show fewer
- Previous pregnancy affected by a neural tube defect (i.e., who have had a fetus diagnosed as affected by a neural tube defect or have given birth to a baby with a neural tube defect) (will be referred to OB/GYN for standard of care, including folic acid supplementation, and excluded)
- Planning to become pregnant (or planning to have a child) in the next 12 months (will be referred to OB/GYN for standard of care, including folic acid supplementation, and be excluded)
- Daily micronutrient supplements (i.e., tablets, capsules, dispersible tablets; ≥4 times in the past week)
- Intramuscular or intravenous interventions containing medications or micronutrients (e.g., iron, vitamin B12, folic acid) in the past 3 months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized Trial of Quadruple Fortified Salt for Anemia and Birth Defects Prevention in Southern India
Women of reproductive age are at an increased risk of anemia and micronutrient deficiencies. Evidence supports the role of periconceptional nutrition in the development of neural tube defects and other pregnancy complications. Vitamin B12 deficiency is a risk factor for neural tube defects and may modify folate biomarkers that predict neural tube defect risk at the population level. There is an interest in mandatory fortification with vitamin B12 and folic acid for anemia and birth defect prevention. However, there are limited population-representative data needed to inform policy and guidelines. This randomized trial will be conducted to evaluate the efficacy of quadruple-fortified salt (QFS; iron, iodine, folic acid, vitamin B12) in 1,000 women and their households in Southern India.
Read the detailed description
Women of reproductive age are at increased risk for anemia and micronutrient deficiencies, due in part to social structures and increased nutritional requirements across the conceptional period. Anemia is an important public health problem and has been associated with risk of adverse pregnancy outcomes, including maternal and infant mortality, preterm delivery, and low birth weight. Iron deficiency is the leading cause of anemia worldwide, accounting for 20% to half of the anemia cases. Deficiencies in folate and/or vitamin B12 also result in megaloblastic anemia, and inadequate periconceptional folate and vitamin B12 status have been linked to pregnancy complications, including birth defects.
Neural tube defects are among the most common and debilitating birth defects in the United States and globally. Neural tube defects are structural birth defects that arise when the neural folds fail to fuse entirely during early embryogenesis. It is estimated that there are over 260,000 cases of neural tube defects per year globally, ranging from 1 to 80 per 10,000 births, with higher prevalence in low- and middle-income countries. India has one of the highest burdens of neural tube defects in the world, accounting for over one-third of all neural tube defects globally.
The links between maternal folate status and neural tube defect risk in offspring have been well established. In randomized trials, periconceptional folic acid supplementation reduced the risk of neural tube defects by approximately 70%. Fortification of staple foods with folic acid is one of the most efficacious and cost-effective public health interventions and has been linked to decreased neural tube defects in national folic acid fortification programs. Fortification interventions to date have primarily targeted wheat (and maize) flour, which are not primary staples in some settings with the highest burden of neural tube defects, such as Southern India and China.
There is increasing interest in fortification strategies targeting additional staple foods and micronutrient deficiencies in at-risk populations. Emerging evidence suggests that vitamin B12 deficiency is associated with an increased risk of neural tube defects independent of folate status and may modify red blood cell folate concentrations which are used to predict risk of neural tube defects at the population level. In Southern India, the setting of this randomized trial, rice is the primary staple and folic acid fortification is not currently mandatory. Findings from a recently completed population-based pre-intervention biomarker survey in this setting demonstrated a substantial burden of anemia and micronutrient deficiencies of iron, vitamin B12, and folate in women of reproductive age. Together, these findings underscore the potential benefits of developing additional fortification strategies to deliver folic acid and other micronutrients for prevention of anemia and neural tube defects.
Salt fortification is a promising strategy to prevent multiple micronutrient deficiencies, as it is widely consumed, affordable, and has existing production and distribution systems. In India, salt is one of the most widely consumed and fortifiable foods, and double-fortified salt (i.e., with iron and iodine) is included in the national fortification guidelines and social safety net programs in India for prevention of anemia and iron deficiency. Randomized trials demonstrated that double-fortified salt significantly improved serum ferritin or iron deficiency in women of reproductive age and school children. Findings from meta-analyses suggest that double-fortified salt improves hemoglobin concentrations and decreases risk of anemia; however, findings from double-fortified salt trials in India for anemia have been heterogeneous. For example, in a randomized trial of double-fortified salt among Indian female tea pickers by Haas et al., double-fortified salt improved hemoglobin, serum ferritin, total body iron, and soluble transferrin receptor levels, compared with iodized salt without iron, after adjusting for the respective baseline bio- markers. However, the prevalence of anemia (53%) as well as vitamin B12 (37%) and folate (86%) deficiencies remained high at endpoint. These findings highlight the need to develop additional interventions to target other nutritional causes of anemia and multiple micronutrient deficiencies (i.e., vitamin B12 and folate).
Recent technological advances informed the development of a quadruple-fortified salt - i.e., iodine, iron, folic acid, and vitamin B12, which can be adjusted to the level of salt intake in populations. Quadruple-fortified salt has undergone preliminary testing for organoleptic properties and consumer acceptability and is ready for use in randomized efficacy trials in human populations.
The objective of this randomized trial is to evaluate the efficacy of quadruple-fortified salt-i.e., iodine, iron, folic acid, and vitamin B12-on improving 1) hemoglobin, 2) red blood cell folate and serum folate, and 3) vitamin B12 concentrations, among women of reproductive age in Southern India.
- Conditions
- Anemia, Folate Deficiency, Vitamin B 12 Deficiency
- Being tested
- + Folic acid, + Vitamin B12, DFS
- Medical subject headings
- Anemia, Folic Acid Deficiency, Vitamin B 12 Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
+ Folic acidOther
Salt fortified with folic acid
+ Vitamin B12Other
Salt fortified with vitamin B12
DFSOther
Salt fortified with iron and iodine
| Study group | Role | What they receive |
|---|---|---|
| Quadruple-Fortified Salt (QFS) | Experimental | Salt fortified with iron, iodine, folic acid, and vitamin B12 Receives: Other: + Folic acid; Other: + Vitamin B12; Other: DFS |
| DFS + Folic acid | Experimental | Salt fortified with iron, iodine, and folic acid Receives: Other: + Folic acid; Other: DFS |
| DFS + Vitamin B12 | Experimental | Salt fortified with iron, iodine, and vitamin B12 Receives: Other: + Vitamin B12; Other: DFS |
| Double-fortified salt (DFS) | Active comparator | Salt fortified with iron and iodine Receives: Other: DFS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentrations of erythrocyte folate and serum folate
Erythrocyte folate and serum folate concentrations, nmol/L
Measured: Endpoint (12 months)
Concentrations of hemoglobin
Hemoglobin concentrations, g/dL
Measured: Endpoint (12 months)
Concentrations of vitamin B12
Vitamin B12 concentrations, pmol/L
Measured: Endpoint (12 months)
Secondary outcomes (3)
Folate deficiency and insufficiency
Erythrocyte (RBC) folate <305.0 nmol/L; <748.0 nmol/L
Measured: Endpoint (12 months)
Anemia
Hemoglobin <12.0 g/dL
Measured: Endpoint (12 months)
Vitamin B12 deficiency and insufficiency
Total vitamin B12 <148.0 pmol/L; <221.0 pmol/L
Measured: Endpoint (12 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2019
- Study start1 Oct 2023
- Primary completionDec 2024 (estimated)
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for AnemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- After confirming eligibility and informed consent/assent, women will be randomly assigned to one of the 4 intervention arms, using a 2 X 2 factorial design: 1. Quadruple-fortified salt (QFS; i.e., iron, iodine, folic acid, and vitamin B12) 2. DFS + folic acid 3. DFS + vitamin B12; and 4. Double-fortified salt (DFS; i.e., iron and iodine)
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cornell University
- Sponsor type
- University, hospital or other
- Collaborators
- Centers for Disease Control and Prevention, Arogyavaram Medical Centre
- Responsible party
- Sponsor
- Investigators
- Julia L Finkelstein, MPH SM ScD, Principal investigator, Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03853304
- Sponsor's protocol ID
- 86613
- Acronym
- QFS
- Status last verified
- Mar 2024
- First submitted
- 22 Feb 2019
- Last updated
- 1 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Williams JL, Bonam W, Crider KS. Anemia and Vitamin B-12 and Folate Status in Women of Reproductive Age in Southern India: Estimating Population-Based Risk of Neural Tube Defects. Curr Dev Nutr. 2021 Apr 26;5(5):nzab069. doi: 10.1093/cdn/nzab069. eCollection 2021 May.
PubMed 34027296Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Krisher JT, Ruth CJ, Mehta R, Williams JL, Bonam W, Crider KS. Periconceptional surveillance for prevention of anaemia and birth defects in Southern India: protocol for a biomarker survey in women of reproductive age. BMJ Open. 2020 Oct 29;10(10):e038305. doi: 10.1136/bmjopen-2020-038305.
PubMed 33122315Finkelstein JL, Guetterman HM, Fothergill A, Johnson CB, Qi YP, Jabbar S, Zhang M, Pfeiffer CM, Rose CE, Yeung LF, Williams JL, Krisher JT, Ruth C, Roy Choudhury D, Venkatramanan S, Haas JD, Kuriyan R, Mehta S, Bonam W, Crider KS. A Randomized Trial of Quadruple-Fortified Salt for Anemia and Birth Defects Prevention in Southern India: Protocol Design and Methods. Curr Dev Nutr. 2023 Feb 21;7(3):100052. doi: 10.1016/j.cdnut.2023.100052. eCollection 2023 Mar.
PubMed 37181934Finkelstein JL, Fothergill A, Guetterman HM, Johnson CB, Bose B, Qi YP, Rose CE, Williams JL, Mehta S, Kuriyan R, Bonam W, Crider KS. Iron status and inflammation in women of reproductive age: A population-based biomarker survey and clinical study. Clin Nutr ESPEN. 2022 Jun;49:483-494. doi: 10.1016/j.clnesp.2022.02.123. Epub 2022 Mar 5.
PubMed 35623855Guetterman HM, Rajagopalan K, Fox AM, Johnson CB, Fothergill A, George N, Krisher JT, Haas JD, Mehta S, Williams JL, Crider KS, Finkelstein JL. A Randomized Crossover Trial of Acceptability of Quadruple-Fortified Salt in Women and their Households in Southern India. J Nutr. 2025 Jan;155(1):322-337. doi: 10.1016/j.tjnut.2024.10.037. Epub 2024 Oct 26.
PubMed 39490799
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Trial of Quadruple Fortified Salt for Anemia and Birth Defects Prevention in Southern India
- ClinicalTrials.gov ID
- NCT03853304
- Acronym / sponsor ID
- QFS / 86613
- Conditions
- Anemia, Folate Deficiency, Vitamin B 12 Deficiency
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Cornell UniversityUniversity, hospital or other
- Collaborators
- Centers for Disease Control and Prevention, Arogyavaram Medical Centre
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- Dec 2024 (estimated)
- Study completion
- Dec 2024 (estimated)
- First posted
- 25 Feb 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Women of reproductive age are at an increased risk of anemia and micronutrient deficiencies. Evidence supports the role of periconceptional nutrition in the development of neural tube defects and other pregnancy complications. Vitamin B12 deficiency is a risk factor for neural tube defects and may modify folate biomarkers that predict neural tube defect risk at the population level. There is an interest in mandatory fortification with vitamin B12 and folic acid for anemia and birth defect prevention. However, there are limited population-representative data needed to inform policy and guidelines. This randomized trial will be conducted to evaluate the efficacy of quadruple-fortified salt (QFS; iron, iodine, folic acid, vitamin B12) in 1,000 women and their households in Southern India.
Detailed description
Women of reproductive age are at increased risk for anemia and micronutrient deficiencies, due in part to social structures and increased nutritional requirements across the conceptional period. Anemia is an important public health problem and has been associated with risk of adverse pregnancy outcomes, including maternal and infant mortality, preterm delivery, and low birth weight. Iron deficiency is the leading cause of anemia worldwide, accounting for 20% to half of the anemia cases. Deficiencies in folate and/or vitamin B12 also result in megaloblastic anemia, and inadequate periconceptional folate and vitamin B12 status have been linked to pregnancy complications, including birth defects.
Neural tube defects are among the most common and debilitating birth defects in the United States and globally. Neural tube defects are structural birth defects that arise when the neural folds fail to fuse entirely during early embryogenesis. It is estimated that there are over 260,000 cases of neural tube defects per year globally, ranging from 1 to 80 per 10,000 births, with higher prevalence in low- and middle-income countries. India has one of the highest burdens of neural tube defects in the world, accounting for over one-third of all neural tube defects globally.
The links between maternal folate status and neural tube defect risk in offspring have been well established. In randomized trials, periconceptional folic acid supplementation reduced the risk of neural tube defects by approximately 70%. Fortification of staple foods with folic acid is one of the most efficacious and cost-effective public health interventions and has been linked to decreased neural tube defects in national folic acid fortification programs. Fortification interventions to date have primarily targeted wheat (and maize) flour, which are not primary staples in some settings with the highest burden of neural tube defects, such as Southern India and China.
There is increasing interest in fortification strategies targeting additional staple foods and micronutrient deficiencies in at-risk populations. Emerging evidence suggests that vitamin B12 deficiency is associated with an increased risk of neural tube defects independent of folate status and may modify red blood cell folate concentrations which are used to predict risk of neural tube defects at the population level. In Southern India, the setting of this randomized trial, rice is the primary staple and folic acid fortification is not currently mandatory. Findings from a recently completed population-based pre-intervention biomarker survey in this setting demonstrated a substantial burden of anemia and micronutrient deficiencies of iron, vitamin B12, and folate in women of reproductive age. Together, these findings underscore the potential benefits of developing additional fortification strategies to deliver folic acid and other micronutrients for prevention of anemia and neural tube defects.
Salt fortification is a promising strategy to prevent multiple micronutrient deficiencies, as it is widely consumed, affordable, and has existing production and distribution systems. In India, salt is one of the most widely consumed and fortifiable foods, and double-fortified salt (i.e., with iron and iodine) is included in the national fortification guidelines and social safety net programs in India for prevention of anemia and iron deficiency. Randomized trials demonstrated that double-fortified salt significantly improved serum ferritin or iron deficiency in women of reproductive age and school children. Findings from meta-analyses suggest that double-fortified salt improves hemoglobin concentrations and decreases risk of anemia; however, findings from double-fortified salt trials in India for anemia have been heterogeneous. For example, in a randomized trial of double-fortified salt among Indian female tea pickers by Haas et al., double-fortified salt improved hemoglobin, serum ferritin, total body iron, and soluble transferrin receptor levels, compared with iodized salt without iron, after adjusting for the respective baseline bio- markers. However, the prevalence of anemia (53%) as well as vitamin B12 (37%) and folate (86%) deficiencies remained high at endpoint. These findings highlight the need to develop additional interventions to target other nutritional causes of anemia and multiple micronutrient deficiencies (i.e., vitamin B12 and folate).
Recent technological advances informed the development of a quadruple-fortified salt - i.e., iodine, iron, folic acid, and vitamin B12, which can be adjusted to the level of salt intake in populations. Quadruple-fortified salt has undergone preliminary testing for organoleptic properties and consumer acceptability and is ready for use in randomized efficacy trials in human populations.
The objective of this randomized trial is to evaluate the efficacy of quadruple-fortified salt-i.e., iodine, iron, folic acid, and vitamin B12-on improving 1) hemoglobin, 2) red blood cell folate and serum folate, and 3) vitamin B12 concentrations, among women of reproductive age in Southern India.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- After confirming eligibility and informed consent/assent, women will be randomly assigned to one of the 4 intervention arms, using a 2 X 2 factorial design: 1. Quadruple-fortified salt (QFS; i.e., iron, iodine, folic acid, and vitamin B12) 2. DFS + folic acid 3. DFS + vitamin B12; and 4. Double-fortified salt (DFS; i.e., iron and iodine)
| Arm | Type | Receives |
|---|---|---|
| Quadruple-Fortified Salt (QFS) | Experimental | Other: + Folic acid, Other: + Vitamin B12, Other: DFSSalt fortified with iron, iodine, folic acid, and vitamin B12 |
| DFS + Folic acid | Experimental | Other: + Folic acid, Other: DFSSalt fortified with iron, iodine, and folic acid |
| DFS + Vitamin B12 | Experimental | Other: + Vitamin B12, Other: DFSSalt fortified with iron, iodine, and vitamin B12 |
| Double-fortified salt (DFS) | Active comparator | Other: DFSSalt fortified with iron and iodine |
Who may qualify
- Ages
- 18 to 49 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Women between 18 and 49 years of age
- Healthy
- Not pregnant or lactating
- Plan to reside in the catchment area of our periconceptional surveillance program for at least two years
Key exclusion criteria (10 listed)
- Severe anemia (Hemoglobin <8.0 g/dL)
- Reported diagnosis of HIV, malaria infection, or active tuberculosis disease
- Malabsorption disorders (i.e., medical conditions that may affect vitamin B12 absorption or metabolism)
- Stage 2 hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg)
- Glycated hemoglobin (HbA1c) ≥6.5%
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| + Folic acidSalt fortified with folic acid | Other | DFS + Folic acid, Quadruple-Fortified Salt (QFS) |
| + Vitamin B12Salt fortified with vitamin B12 | Other | DFS + Vitamin B12, Quadruple-Fortified Salt (QFS) |
| DFSSalt fortified with iron and iodine | Other | DFS + Folic acid, DFS + Vitamin B12, Double-fortified salt (DFS), Quadruple-Fortified Salt (QFS) |
Primary outcome
Concentrations of erythrocyte folate and serum folate
Time frame: Endpoint (12 months)
Erythrocyte folate and serum folate concentrations, nmol/L
Concentrations of hemoglobin
Time frame: Endpoint (12 months)
Hemoglobin concentrations, g/dL
Concentrations of vitamin B12
Time frame: Endpoint (12 months)
Vitamin B12 concentrations, pmol/L
3 secondary outcomes
Folate deficiency and insufficiency
Time frame: Endpoint (12 months)
Anemia
Time frame: Endpoint (12 months)
Vitamin B12 deficiency and insufficiency
Time frame: Endpoint (12 months)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2024.
- Background: PubMed 34027296Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Williams JL, Bonam W, Crider KS. Anemia and Vitamin B-12 and Folate Status in Women of Reproductive Age in Southern India: Estimating Population-Based Risk of Neural Tube Defects. Curr Dev Nutr. 2021 Apr 26;5(5):nzab069. doi: 10.1093/cdn/nzab069. eCollection 2021 May.
- Background: PubMed 33122315Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Krisher JT, Ruth CJ, Mehta R, Williams JL, Bonam W, Crider KS. Periconceptional surveillance for prevention of anaemia and birth defects in Southern India: protocol for a biomarker survey in women of reproductive age. BMJ Open. 2020 Oct 29;10(10):e038305. doi: 10.1136/bmjopen-2020-038305.
- Background: PubMed 37181934Finkelstein JL, Guetterman HM, Fothergill A, Johnson CB, Qi YP, Jabbar S, Zhang M, Pfeiffer CM, Rose CE, Yeung LF, Williams JL, Krisher JT, Ruth C, Roy Choudhury D, Venkatramanan S, Haas JD, Kuriyan R, Mehta S, Bonam W, Crider KS. A Randomized Trial of Quadruple-Fortified Salt for Anemia and Birth Defects Prevention in Southern India: Protocol Design and Methods. Curr Dev Nutr. 2023 Feb 21;7(3):100052. doi: 10.1016/j.cdnut.2023.100052. eCollection 2023 Mar.
- Background: PubMed 35623855Finkelstein JL, Fothergill A, Guetterman HM, Johnson CB, Bose B, Qi YP, Rose CE, Williams JL, Mehta S, Kuriyan R, Bonam W, Crider KS. Iron status and inflammation in women of reproductive age: A population-based biomarker survey and clinical study. Clin Nutr ESPEN. 2022 Jun;49:483-494. doi: 10.1016/j.clnesp.2022.02.123. Epub 2022 Mar 5.
- Derived from this study: PubMed 39490799Guetterman HM, Rajagopalan K, Fox AM, Johnson CB, Fothergill A, George N, Krisher JT, Haas JD, Mehta S, Williams JL, Crider KS, Finkelstein JL. A Randomized Crossover Trial of Acceptability of Quadruple-Fortified Salt in Women and their Households in Southern India. J Nutr. 2025 Jan;155(1):322-337. doi: 10.1016/j.tjnut.2024.10.037. Epub 2024 Oct 26.
- Individual participant dataSharing planned: No
Related trials for Anemia
RecruitingPhase 1/2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Aplastic Anemia, Refractory
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julia L Finkelstein, MPH SM ScD principal investigator
Cornell University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing + Folic acid, + Vitamin B12 and DFS in people with Anemia and Folate Deficiency, run by Cornell University at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentrations of erythrocyte folate and serum folate (time frame: Endpoint (12 months)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03853304, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2024.